Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment

Review

Expert Opinion on Drug Metabolism & Toxicology, 15:2,113-120, DOI: 10.1080/17425255.2019.1568409
 

Introduction: Asthma is a chronic inflammatory airway disease. It occurs in a ‘severe’ form in about 8–10% of asthmatic patients. In the last decade, the development of biological drugs (e.g. monoclonal antibodies) allowed to efficiently approach severe asthma. The current therapeutic targets available are mainly those related to TH2 inflammation.

Areas covered: The main pharmacokinetic and pharmacodynamic characteristics of the monoclonal antibodies against IL-5, IL-5Ra, IL4-IL13, and IgE, that are currently marketed or understood for severe asthma are discussed in this paper.

Expert opinion: The currently available biological drugs represent an excellent therapeutic add-on to traditional drugs, especially in replacing systemic corticosteroid therapies. The different pharmacokinetic and pharmacodynamic characteristics of the drugs, despite sometime sharing the same target, would allow a better personalization of the therapy, tailoring the treatment to the characteristics of the patient.

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Interasma - CME:Unlocking the Door to Asthma Control: Key Factors for Therapy Selection and Medication Management https://t.co/CiCJQvIgF9
6hreplyretweetfavorite
Interasma RT @EAACI_HQ: Read this article! RNA‐specific toll-like receptors #TLR are important in immunity against various pathogens but an inadequat…
7hreplyretweetfavorite
Interasma RT @worldallergy: Top story: This Is Why Food Allergies Are on the Rise, According to Experts https://t.co/oySQs4f4jq, see more https://t.c…
7hreplyretweetfavorite
Interasma RT @worldallergy: WAO Tweeted Times https://t.co/1tA4uy3LDq - top stories by @ARIAGuideline, @Interasma
7hreplyretweetfavorite
Interasma RT @worldallergy: Top story: POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Heal…
7hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma